Ventilator Associated Pneumonia (VAP) - Pipeline Insight, 2024

This “Ventilator Associated Pneumonia - Pipeline Insight, 2024,” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Ventilator Associated Pneumonia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Ventilator Associated Pneumonia Understanding

Ventilator Associated Pneumonia: Overview

Ventilator-associated pneumonia is defined as pneumonia occurring more than 48 h after patients have been intubated and received mechanical ventilation. Diagnosing VAP requires a high clinical suspicion combined with bedside examination, radiographic examination, and microbiologic analysis of respiratory secretions. Aggressive surveillance is vital in understanding local factors leading to VAP and the microbiologic milieu of a given unit. Judicious antibiotic usage is essential, as resistant organisms continue to plague intensive care units and critically ill patients. The mortality in ventilator-associated pneumonia is high despite the availability of effective antibiotics. However, not all mortality is attributable to the pneumonia itself; many of the deaths are related to the patient's underlying illness. Adequacy of initial antimicrobial therapy clearly improves prognosis. Infection with antibiotic-resistant gram-negative or gram-positive bacteria worsens prognosis. Ventilator-associated pneumonia (VAP) has traditionally been treated with a 14-21-day course of antibiotics. However, prolonged antibiotic therapy is associated with the emergence of multidrug-resistant strains, as well as higher toxicity and costs.

Ventilator Associated Pneumonia - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ventilator Associated Pneumonia pipeline landscape is provided which includes the disease overview and Ventilator Associated Pneumonia treatment guidelines. The assessment part of the report embraces, in depth Ventilator Associated Pneumonia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ventilator Associated Pneumonia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

In April 2022, Entasis Therapeutics Presented Efficacy and Safety Data from Landmark Phase III ATTACK Trial at ECCMID 2022 Conference. The trial consisted of two parts: Part A was a randomized, blinded noninferiority study (SUL-DUR versus colistin; non-inferiority margin 20%) in ABC hospital-acquired pneumonia, ventilator-associated bacterial pneumonia, ventilated pneumonia, or bacteremia; Part B was an open label study (SUL-DUR only) that enrolled patients with ABC infections.- Aridis Pharmaceuticals has continued enrollment in the Company's Phase III study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis is on track to report top-line data in the second half of 2022.

• In March 2022, Spero Therapeutics reported topline results from Phase I bronchoalveolar lavage trial support further development of SPR206 in the setting of hospital-acquired pneumonia and ventilator-associated pneumonia.

Ventilator Associated Pneumonia Emerging Drugs Chapters

This segment of the Ventilator Associated Pneumonia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ventilator Associated Pneumonia Emerging Drugs

AR-301: Aridis Pharmaceuticals AR-301 (tosatoxumab) is being evaluated in a Phase III clinical study as an adjunctive treatment to standard of care antibiotics in S. aureus VAP patients. The ongoing AR-301 Phase III study remains blinded, and the independent Data Monitoring Committee with access to unblinded data continues to monitor study subjects for safety and has not expressed any safety concerns. The Company has observed modest improvement in enrollment in recent months despite the continued pandemic. However, because a significant number of participating clinical sites in the study are in Eastern Europe, the escalating Ukraine-Russia conflict is expected to negatively impact enrollment. At the present time, the company anticipates reporting top-line data in the second half of 2022.

ETX 2514/Sulbactam: Entasis Therapeutics Durlobactam (DUR; previously designated ETX2514) is our novel, broad-spectrum and potent inhibitor of Class A, C, and D ß-lactamases. Sulbactam (SUL) is a ß-lactam antibiotic with activity against Acinetobacter baumannii; however, ß-lactamase-mediated resistance to sulbactam is now widespread rendering it generally ineffective. In preclinical studies, durlobactam inhibits the ß-lactamases commonly found in A. baumannii thus restoring sulbactam’s activity. The company is developing SUL-DUR (previously designated ETX2514SUL), a combination of ß-lactam antibiotic and a ß-lactamase inhibitor for the treatment of serious infections cuased by Acinetobacter, including multidrug-resistant (MDR) strains.

In April 2022, Entasis Therapeutics reported positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase III ATTACK trial. The trial consisted of two parts: Part A was a randomized, blinded noninferiority study (SUL-DUR versus colistin; non-inferiority margin 20%) in ABC hospital-acquired pneumonia, ventilator-associated bacterial pneumonia, ventilated pneumonia, or bacteremia; Part B was an open label study (SUL-DUR only) that enrolled patients with ABC infections who did not tolerate colistin/polymyxin B or whose pathogens were resistant to colistin/polymyxin B. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity. NDA submission is planned for mid-2022.

Ventilator Associated Pneumonia: Therapeutic Assessment

This segment of the report provides insights about the different Ventilator Associated Pneumonia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ventilator Associated Pneumonia

There are approx. 13+ key companies which are developing the therapies for Ventilator Associated Pneumonia. The companies which have their Ventilator Associated Pneumonia drug candidates in the most advanced stage, i.e. phase III include, Aridis Pharmaceuticals.

Phases

This report covers around 13+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Ventilator Associated Pneumonia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ventilator Associated Pneumonia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ventilator Associated Pneumonia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ventilator Associated Pneumonia drugs.

Ventilator Associated Pneumonia Report Insights

• Ventilator Associated Pneumonia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ventilator Associated Pneumonia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Ventilator Associated Pneumonia drugs?
• How many Ventilator Associated Pneumonia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ventilator Associated Pneumonia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ventilator Associated Pneumonia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ventilator Associated Pneumonia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Aridis Pharmaceuticals
• Pfizer
• Entasis Therapeutics
• Cumberland Pharmaceuticals
• Venatorx Pharmaceuticals
• Spero Therapeutics
• Bio VersysAG
• Antabio
• Helperby Therapeutics
• Nabriva Therapeutics
• Nosopharm
• Qpex Biopharma
• Phico Therapeutics

Key Products

• AR-301
• Suvratoxumab
• AR-105
• AR-101
• ETX2514
• cefepime-taniborbactam
• Vibativ
• SPR206
• BV100
• ANT3310
• HY-011B4
• HY-012B5
• HY-015B12
• PT3.9

This product will be delivered within 1-3 business days.